Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women,~* 18years and older~* American Society of Anesthesiologists 1, 2,3,~* planned for radical mastectomy.~Exclusion Criteria:~* Neurological problems (central and peripheral)~* Bilateral mastectomy~* Body Mass Index \> 33,~* Absolute contra-indication for ketorolac.~* Allergy/over-sensitiveness to levobupivacaine or local anesthetics of the same class~* Allergy/over-sensitiveness to dexmedetomidine or other alpha2 agonists (clonidine)~* Anatomic variations of the breast, pectoral region or axilla, noticed at clinical examination, including a pacemaker, Implantable Cardioverter Defibrillator, Port-a-Cath or other implantable device on the side that needs surgery.~* Participation in an other clinical trial within a period of four weeks before the beginning of this trial.~* Coagulopathy~* Infection or abcess in the region where the Block will be placed.~* Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levobupivacaine (Type: ACTIVE_COMPARATOR): Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
- Levobupivacaine + Dexmedetomidine (Type: ACTIVE_COMPARATOR): Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).

Based on this trial design, predict the completion outcome and termination type (if applicable).